---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-028853"
form_type: "8-K"
ticker: "NUVL"
cik: "0001861560"
company_name: "Nuvalent, Inc."
filed_at: "2022-08-10T23:59:59+00:00"
generated_at: "2026-06-24T01:35:58.343431+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Nuvalent reports Q2 2022 net loss of $18.5M; pipeline on track with NVL-520 data expected H2 2022

## Summary
- Net loss of $18.5M ($0.38 per share); cash, equivalents and marketable securities $257.0M expected to fund operations into 2024.
- R&D expenses $13.6M, G&A $5.2M for Q2 2022.
- Preliminary dose-escalation data from Phase 1 ARROS-1 trial (NVL-520 for ROS1+ NSCLC) anticipated in H2 2022.
- Dosing initiated in Phase 1 ALKOVE-1 trial (NVL-655 for ALK+ NSCLC); new preclinical data presented at WCLC 2022.
- On track to select two additional development candidates in H2 2022 for ALK compound resistance mutations and HER2 Exon 20 insertions.

## SEC filing metadata
- accession: 0001564590-22-028853
- form_type: 8-K
- ticker: NUVL
- cik: 0001861560
- company_name: Nuvalent, Inc.
- filed_at: 2022-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1861560/000156459022028853/0001564590-22-028853-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1861560/000156459022028853/nuvl-8k_20220810.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-028853
- JSON: https://secwatch.observer/filing/0001564590-22-028853.json
- Plain text: https://secwatch.observer/filing/0001564590-22-028853.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.